Get the Daily Brief
Latest Biotech News
CagriSema falls short: Lilly’s Zepbound wins head‑to‑head
Novo Nordisk said its investigational obesity combination CagriSema produced 23% mean weight loss in a late‑stage head‑to‑head trial but was outperformed by Eli Lilly’s marketed tirzepatide...
Gossamer’s PAH program fails — clinical miss and stock rout
Gossamer Bio disclosed that its Phase 3 PROSERA trial of seralutinib in pulmonary arterial hypertension missed the primary endpoint, producing a non‑statistically significant 13‑meter six‑minute...
Illumina maps NovaSeq X upgrades — Ultima counters with UG200...
Illumina announced a roadmap of hardware and chemistry improvements for its NovaSeq X platform to boost read output, speed and accuracy—promising new 5 billion‑read flow cells, a 600‑cycle kit for...
Syndex raises $15.5M seed: mcPCR aims to boost methylation diagnostics
UK startup Syndex Bio closed a $15.5 million seed round led by Arch Venture Partners to advance mcPCR, a methylation‑preserving PCR method intended to retain 5‑methylcytosine during amplification....
Candel secures two‑pronged $200M financing to back prostate gene therapy
Candel Therapeutics executed two financing transactions that could generate up to $200 million to support commercialization of CAN‑2409 (aglatimagene besadenovec), its intraprostatic...
MoonLake’s IL‑17 nanobody posts Phase 2 win; company readies filing
MoonLake Immunotherapeutics reported positive Phase 2 data for sonelokimab, an IL‑17 nanobody, in axial spondyloarthritis—achieving an ASAS40 response in 81% of participants at Week 12 and showing...
Vanda wins FDA nod for Bysanti — atypical antipsychotic cleared
Vanda Pharmaceuticals received FDA approval for Bysanti (milsaperidone) for acute treatment of bipolar I disorder and schizophrenia, preserving the company’s atypical antipsychotic franchise as...
VC shifts to late‑stage bets: PitchBook finds $33.8B in 2025 funding
PitchBook released its 2025 biopharma VC analysis showing $33.8 billion deployed across 1,171 deals, with capital concentrating on later‑stage and asset‑centric companies. The report documents a...
Gilead to buy Arcellx for $7.8B — moves to control near‑approval CAR‑T
Gilead Sciences agreed to acquire Arcellx in a cash deal valuing the CAR‑T developer at about $7.8 billion. The deal consolidates Gilead’s stake in anito‑cel, a BCMA‑directed CAR‑T therapy that is...
FDA reopens Moderna flu‑vaccine review: PDUFA Aug. 5 set
The FDA agreed to advance Moderna’s mRNA seasonal flu vaccine application after a Type A meeting, reversing a prior refuse‑to‑file action and assigning a PDUFA date of August 5. Moderna proposed a...
Syndex closes $15.5M seed to preserve methylation in PCR workflows
Syndex Bio raised $15.5 million in a seed round led by Arch Venture Partners to commercialize mcPCR, a technique the company says preserves DNA methylation during amplification. The Cambridge,...
Ultima Genomics launches UG200: cheaper, faster high‑throughput sequencer
Ultima Genomics unveiled its UG200 series of high‑throughput sequencers and a Solaris 2.0 workflow that the company says halves run time while improving data quality. The UG200 carries a list...
Complete Genomics to shift from Chinese parent—Swiss Rockets moves in
Complete Genomics agreed to be acquired by Swiss incubator Swiss Rockets, ending nearly 13 years of ownership tied to MGI Tech. The deal, announced with customary closing conditions and...
Korsana raises $175M to advance brain‑penetrant Alzheimer’s antibodies
Korsana Biosciences disclosed a $175 million financing to develop a preclinical Alzheimer’s antibody program that uses a platform to shuttle antibodies across the blood‑brain barrier. The company...
MoonLake posts Phase 2 win for IL‑17 nanobody sonelokimab in axSpA
MoonLake Immunotherapeutics reported positive Phase 2 results for sonelokimab, a subcutaneous IL‑17 nanobody, achieving the primary ASAS40 endpoint in patients with axial spondyloarthritis...
Lilly’s Zepbound edges Novo’s CagriSema — head‑to‑head loss dents Novo shares
A head‑to‑head trial (REDEFINE 4) showed Eli Lilly’s marketed obesity drug Zepbound outperformed Novo Nordisk’s GLP‑1/amylin combo CagriSema, with Novo reporting that CagriSema did not match...
Forbion, Sanofi lead $75M to push Altesa’s vapendavir into Phase IIb
Altesa BioSciences closed a $75 million Series B led by Forbion with participation from Sanofi to fund a Phase IIb CARDINAL study of vapendavir, an oral antiviral targeting rhinovirus‑driven COPD...
Gossamer’s pulmonary arterial hypertension drug misses Phase 3 — company still pursuing approval
Gossamer Bio announced its Phase 3 PROSERA trial failed to meet the primary endpoint for seralutinib in pulmonary arterial hypertension (PAH); the observed six‑minute walk distance improvement did...
Zepbound tops CagriSema: REDEFINE 4 reshuffles obesity race
Eli Lilly’s marketed obesity drug Zepbound produced greater clinical benefit than Novo Nordisk’s GLP-1/amylin combo CagriSema in the head‑to‑head REDEFINE 4 trial, Novo reported. The company...
FDA reopens Moderna flu review: Type A meeting clears pathway
The U.S. Food and Drug Administration agreed to rescind a prior refuse‑to‑file posture and will review Moderna’s seasonal flu candidate mRNA‑1010 after a Type A meeting, the company said, with a...